Advances in Multiple Myeloma from EHA 2013

An update from Myeloma UK

Newly diagnosed multiple myeloma patients

Anaemia update from EHA 2013

Chronic lymphocytic leukaemia update from EHA 2013

Advances in Multiple Myeloma from EHA 2013

Acute myeloid leukaemia (AML) at EHA 2013

The future management of mantle cell lymphoma

Relapsed or progressive multiple myeloma

Pomalidomide prolongs survival in refractory multiple myeloma patients

Carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed multiple myeloma

Age and ageing in blood disorders

Rituximab for b-cell lymphoma and EHA overview

Highlights from EHA 2013

Patient advocacy track 'personalised medicine'

Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide

Challenges facing haematologists treating acute myeloid leukaemia

JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma

Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia

Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelofibrosis

Strategies to maintain remission in high risk CD19 lymphoid malignancies

Von Willebrand Factor and ADAMTS13

Use of autologous stem cell transplant in multiple myeloma

International workshop on chronic lymphocytic leukaemia 2013

Study shows pomalidomide prolongs survival in refractory myeloma patients

Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma

Targeting JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic leukaemia

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma